Publication: The evaluation of magee equation 2 in predicting response and outcome in hormone receptor-positive and HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
Issued Date
2020-01-01
Resource Type
ISSN
11791322
Other identifier(s)
2-s2.0-85084211127
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cancer Management and Research. Vol.12, (2020), 2491-2499
Suggested Citation
Napat Saigosoom, Doonyapat Sa-Nguanraksa, Eng O-Charoenrat, Thanawat Thumrongtaradol, Pornchai O-Charoenrat The evaluation of magee equation 2 in predicting response and outcome in hormone receptor-positive and HER2-negative breast cancer patients receiving neoadjuvant chemotherapy. Cancer Management and Research. Vol.12, (2020), 2491-2499. doi:10.2147/CMAR.S237423 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/56307
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The evaluation of magee equation 2 in predicting response and outcome in hormone receptor-positive and HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
Other Contributor(s)
Abstract
© 2020 Saigosoom et al. Background and Purpose: Magee Equations have been developed as accurate tools for predicting response and clinical outcomes in breast cancer patients treated with adjuvant systemic therapy using basic clinicopathological parameters. This study aims to evaluate the alternative application of Magee Equation 2 score in predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in hormone receptor (HR)-positive, HER2- negative breast cancer. Patients and Methods: Patients with HR-positive, HER2-negative breast cancer who received NAC from January 2010 to May 2018 at Siriraj Hospital, Mahidol University, Thailand, were recruited. Pre-treatment status of HR andHER2was used to calculate the Magee Equation 2 scores. The pCR rates among different clinicopathological parameters were analyzed. Survival analysis was performed by Log-rank test. Kaplan-Meier survival curves were analyzed. Results: A total of 215 patients were eligible. The pCR rates for low, intermediate, and high scores were 4.8%, 3.6%, and 23.8%, respectively. Patients with high scores had significantly higher size reduction and pCR rates compared to those with intermediate or low scores (p<0.001). Those with high scores had higher rates of locoregional recurrence and death. The patients with high score had significantly lower overall survival (p=0.034). Conclusion: Among patients with HR-positive and HER2-negative breast cancer treated with NAC, Magee Equation 2 might be used as a tool for predicting the pCR and clinical outcome.